Cited 5 time in
A Comprehensive Review of Naringenin, a Promising Phytochemical with Therapeutic Potential
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Shin Jun Hong | - |
| dc.contributor.author | Shin Seung Ho | - |
| dc.date.accessioned | 2025-01-02T07:00:09Z | - |
| dc.date.available | 2025-01-02T07:00:09Z | - |
| dc.date.issued | 2024-12 | - |
| dc.identifier.issn | 1017-7825 | - |
| dc.identifier.issn | 1738-8872 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/75333 | - |
| dc.description.abstract | Disorders, including cancer, metabolic disorders, and neurodegenerative diseases, can threaten human health; therefore, disease prevention is essential. Naringenin, a phytochemical with low toxicity, has been used in various disease prevention studies. This study aimed to comprehensively review the effects of naringenin on human health. First, we introduced the general characteristics of naringenin and its pharmacokinetic features when absorbed in the body. Next, we summarized the inhibitory effects of naringenin on colorectal, gastric, lung, breast, ovarian, cervical, prostate, bladder, liver, pancreatic, and skin cancers in preclinical studies. Lastly, we investigated the inhibitory effects of naringenin on metabolic disorders, including diabetes, obesity, hyperlipidemia, hypertension, cardiac toxicity, hypertrophy, steatosis, liver disease, and arteriosclerosis, as well as on neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. In conclusion, naringenin may serve as a significant natural compound that benefits human health. | - |
| dc.format.extent | 14 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | 한국미생물·생명공학회 | - |
| dc.title | A Comprehensive Review of Naringenin, a Promising Phytochemical with Therapeutic Potential | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.doi | 10.4014/jmb.2410.10006 | - |
| dc.identifier.scopusid | 2-s2.0-85213566270 | - |
| dc.identifier.wosid | 001385289400003 | - |
| dc.identifier.bibliographicCitation | Journal of Microbiology and Biotechnology, v.34, no.12, pp 2425 - 2438 | - |
| dc.citation.title | Journal of Microbiology and Biotechnology | - |
| dc.citation.volume | 34 | - |
| dc.citation.number | 12 | - |
| dc.citation.startPage | 2425 | - |
| dc.citation.endPage | 2438 | - |
| dc.type.docType | Article | - |
| dc.identifier.kciid | ART003149037 | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
| dc.relation.journalResearchArea | Microbiology | - |
| dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
| dc.relation.journalWebOfScienceCategory | Microbiology | - |
| dc.subject.keywordPlus | RENIN-ANGIOTENSIN SYSTEM | - |
| dc.subject.keywordPlus | CANCER CELLS | - |
| dc.subject.keywordPlus | DOWN-REGULATION | - |
| dc.subject.keywordPlus | DEATH RECEPTOR | - |
| dc.subject.keywordPlus | GLUCOSE-UPTAKE | - |
| dc.subject.keywordPlus | MODEL | - |
| dc.subject.keywordPlus | FLAVANONES | - |
| dc.subject.keywordPlus | QUERCETIN | - |
| dc.subject.keywordPlus | DISEASE | - |
| dc.subject.keywordPlus | HEALTH | - |
| dc.subject.keywordAuthor | Phytochemical | - |
| dc.subject.keywordAuthor | naringenin | - |
| dc.subject.keywordAuthor | cancer | - |
| dc.subject.keywordAuthor | metabolic disorder | - |
| dc.subject.keywordAuthor | neurodegenerative disease | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
